To require the Secretary of Health and Human Services to prescribe a regulation reducing the risks in gene synthesis products, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require the Secretary of Health and Human Services to prescribe a regulation reducing the risks in gene synthesis products, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Healthcare, Science & Space.
Who Benefits and How
federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HE5972B4C466A4B3A9E53E6117141D791: 1. Short title This Act may be cited as the Securing Gene Synthesis Act.
- Section H1E95CF00728D4D3FA2BE1480B87BE4AF: 2. Requirements for the dissemination of synthetic genetic material Section 351A of the Public Health Service Act (42 U.S.C. 262a) is amended— in subsection...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require the Secretary of Health and Human Services to prescribe a regulation reducing the risks in gene synthesis products, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Key Policy Areas
Government Operations, Healthcare, Science & Space
Primary Purpose
This bill, To require the Secretary of Health and Human Services to prescribe a regulation reducing the risks in gene synthesis products, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Policy Domains
Whole bill
Identified Gains
- federal agencies and legislative administrators
Identified Costs
- federal implementing agencies
Sponsors
Legislative Progress
IntroducedMs. Eshoo introduced the following bill; which was referred to …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
the minimal length of de novo gene synthesis product which ensures that the results of such screening contain enough information to allow an unambiguous analysis of such product’s potential misuse
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology